Trials / Approved For Marketing
Approved For MarketingNCT00040625
ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed | |
| DRUG | Cisplatin |
Timeline
- First posted
- 2002-07-04
- Last updated
- 2007-03-15
Locations
6 sites across 4 countries: United States, Brazil, Egypt, Saudi Arabia
Source: ClinicalTrials.gov record NCT00040625. Inclusion in this directory is not an endorsement.